Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Baran, R
McKenna, E
Patt, Y
Ghali, N
机构：
[1] Roche Biomed Labs, Nutley, NJ USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3762
引用
收藏
页码：309S / 309S
页数：1
相关论文
共 50 条
  • [21] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [22] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
    Porschen, Rainer
    Kubicka, S.
    Grothey, A.
    Grateven, U.
    Kretzschmar, A.
    Greil, R.
    Freier, W.
    Seufferlein, T.
    Arkenau, Ht
    Hinke, A.
    Schmoll, Hj
    Schmiegel, W.
    GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
  • [23] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A. Meyerhardt
    Jeffrey W. Clark
    Jeffrey G. Supko
    Joseph P. Eder
    Shuji Ogino
    Clinton F. Stewart
    Ferdinando D’Amato
    Janet Dancey
    Peter C. Enzinger
    Andrew X. Zhu
    David P. Ryan
    Craig C. Earle
    Robert J. Mayer
    Ann Michelini
    Kate Kinsella
    Charles S. Fuchs
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 661 - 670
  • [24] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Meyerhardt, Jeffrey A.
    Clark, Jeffrey W.
    Supko, Jeffrey G.
    Eder, Joseph P.
    Ogino, Shuji
    Stewart, Clinton F.
    D'Amato, Ferdinando
    Dancey, Janet
    Enzinger, Peter C.
    Zhu, Andrew X.
    Ryan, David P.
    Earle, Craig C.
    Mayer, Robert J.
    Michelini, Ann
    Kinsella, Kate
    Fuchs, Charles S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 661 - 670
  • [25] CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
    André, T
    Louvet, C
    Maindrault-Goebel, F
    Couteau, C
    Mabro, M
    Lotz, JP
    Gilles-Amar, V
    Krulik, M
    Carola, E
    Izrael, V
    de Gramont, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) : 1343 - 1347
  • [26] Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Berlin, Jordan
    Posey, James
    Tchekmedyian, Simon
    Hu, Eddie
    Chan, David
    Malik, Imtiaz
    Yang, Liqiang
    Amado, Rafael G.
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 427 - 432
  • [27] Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
    Kabbinavar, Fairooz F.
    Wallace, Joel F.
    Holmgren, Eric
    Yi, Jing
    Cella, David
    Yost, Kathleen J.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2008, 13 (09): : 1021 - 1029
  • [28] Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer
    Kono, T
    Ebisawa, Y
    Tomita, I
    Chisato, N
    Kamiya, K
    Asama, T
    Ayabe, T
    Ashida, T
    Kohgo, Y
    Kasai, S
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 224 - 227
  • [29] Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).
    Pectasides, D. G.
    Xanthakis, I.
    Makatsoris, T.
    Samantas, E.
    Varthalitis, I.
    Papaxoinis, G.
    Papakotoulas, P.
    Boumakis, E.
    Papandreou, C.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] First line polichemotherapy (PCT) with irinotecan plus leucovorin plus 5-fluorouracil (FOLFIRI) and bevacizumab in patients (Pts) with metastatic colorectal cancer (MCRC): A phase II study in our institution
    Roda, G.
    Nonnis, D. Carta A.
    Galmozzi, A.
    Nastasi, G.
    Cotroneo, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
12345